Select a Region North America

Expertise

Alberta Spreafico, Ph.D, MBA

Senior Vice President, Health Innovation

Expertise:

Digital Health, Digital Technology

Alberta is a global health strategist, policy expert and advisor and digital health thought leader with 10+ years of experience working at the intersection of industry and academia. She co-founded and directed multiple health innovation development programs worldwide, effectively integrating digital health technologies across healthcare systems and clinical practice.

As SVP of Health Innovation at EVERSANA, Alberta leads health innovation advisory programs enabling co-ideation, scouting and development, commercialization and system readiness.

She also served as Knowledge Partner of the Digital Therapeutics Alliance on DTx Policies in Europe and is a member of the External Advisory board of the European Health Data Space’s HealthData@EU Project, scientific committee member of the Italian Digital Health Association (ASSD); TedX speaker on enhancing access to quality care worldwide and Adjunct Professor of Development Economics and Social Policies at the University of Pavia (Italy).

Articles by Alberta Spreafico, Ph.D, MBA

Digital Therapeutics: A Necessity for Italy – Insights from Roberto Ascione and Alberta Spreafico

A Collaborative Approach to Integrating Digital Therapeutics (DTx) into the Italian Health System  Roberto Ascione, our President, Health Innovation, and Alberta Spreafico, PhD, MBA, Senior Vice President, Health Innovation, have co-authored the Italian publication “Digital Therapeutics: A Necessity for Italy.” This work continues the journey initiated in 2019 with the project “Terapie Digitali per l’Italia” (#DTxITA) and aims to promote the integration of these digital innovations into the Italian health system. The project also supports research, development, and entrepreneurship in Italy, aligning with the global digital medicine context and opportunities.  The publication features contributions from over 40 experts, including clinicians, patients, pharmacists, methodologists, healthcare company directors, economists, legal experts, regulatory […]

The Looming Legacy of Software as a Medical Device (SaMD) Misclassification Under Medical Device Directive (MDD)

Regulation (EU) 2017/745, the Medical Device Regulation (MDR), sent shockwaves through the industry with its stricter oversight and transparency demands. While the implementation challenges like delays, notified body capacity, and EUDAMED implementation have dominated discussions, a potentially bigger issue lurks for software as a medical device (SaMD) previously classified as Class I under the Medical Device Directive (MDD). The structure of the MDD allowed for broad and varied interpretations of the Directive, and some SaMD manufacturers relied upon this leeway to self-classify devices as low-risk Class I. Now, with the MDR in effect, these devices are stuck in a loophole and face serious challenges in meeting the rigors of the […]

Interested in scheduling a meeting or speaking event?

お問い合わせ